Vaxcyte, Inc. $PCVX Shares Purchased by C WorldWide Group Holding A S

C WorldWide Group Holding A S boosted its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 105.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 195,000 shares of the company’s stock after acquiring an additional 100,000 shares during the quarter. C WorldWide Group Holding A S owned 0.15% of Vaxcyte worth $6,339,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of PCVX. Principal Financial Group Inc. boosted its holdings in Vaxcyte by 52.0% during the 1st quarter. Principal Financial Group Inc. now owns 469,561 shares of the company’s stock valued at $17,731,000 after acquiring an additional 160,622 shares during the period. Envestnet Asset Management Inc. boosted its holdings in Vaxcyte by 75.4% during the 1st quarter. Envestnet Asset Management Inc. now owns 96,600 shares of the company’s stock valued at $3,648,000 after acquiring an additional 41,517 shares during the period. Brown Advisory Inc. boosted its holdings in Vaxcyte by 2.5% during the 1st quarter. Brown Advisory Inc. now owns 570,258 shares of the company’s stock valued at $21,533,000 after acquiring an additional 14,049 shares during the period. Nisa Investment Advisors LLC boosted its holdings in Vaxcyte by 10.9% during the 1st quarter. Nisa Investment Advisors LLC now owns 2,977 shares of the company’s stock valued at $112,000 after acquiring an additional 293 shares during the period. Finally, Xponance Inc. boosted its holdings in Vaxcyte by 4.7% during the 1st quarter. Xponance Inc. now owns 9,320 shares of the company’s stock valued at $352,000 after acquiring an additional 415 shares during the period. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Vaxcyte Trading Down 2.5%

Shares of NASDAQ PCVX opened at $40.32 on Thursday. Vaxcyte, Inc. has a twelve month low of $27.66 and a twelve month high of $116.00. The stock has a 50 day moving average of $37.66 and a two-hundred day moving average of $34.87. The stock has a market cap of $5.23 billion, a P/E ratio of -8.33 and a beta of 1.07.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($1.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.29). During the same quarter in the prior year, the firm posted ($0.83) earnings per share. As a group, research analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on PCVX shares. Cowen restated a “buy” rating on shares of Vaxcyte in a report on Thursday, August 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research note on Tuesday, October 14th. Finally, The Goldman Sachs Group initiated coverage on Vaxcyte in a research note on Friday, September 12th. They issued a “neutral” rating and a $38.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $106.25.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.